Premium
Effect of Age and Dose on the Incidence of Adverse Events in the Treatment of Hypertension in Patients Receiving Terazosin
Author(s) -
Hosmane B. S.,
Maurath C. J.,
Jordan D. C.,
Laddu A.
Publication year - 1992
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1992.tb03859.x
Subject(s) - medicine , palpitations , nausea , adverse effect , placebo , incidence (geometry) , anesthesia , terazosin , clinical trial , physics , alternative medicine , pathology , hyperplasia , optics
Selected adverse events were evaluated from the combined randomized placebo‐controlled clinical trials (once‐a‐day or twice‐a‐day; monotherapy or combination therapy) of terazosin in hypertensive patients. The designs of these clinical trials were either titration to response or titration to a fixed dose. A grouped survival methodology using logistic regression, developed by Hosmane et al, was used to study the effects of age and dose on the incidence of adverse events. The analysis indicated that except for palpitations, nausea, headache, and dizziness the incidence of adverse events was not significantly related to either age or dose. Palpitations and headache decreased with increasing age and increasing dose and age, respectively. Dizziness and nausea increased at the maximum dose of 20 mg, but not at the 5‐ or 10‐mg doses.